Guangdong Lifestrong Pharmacy Co., Ltd. (SHE:301111)
19.90
+0.26 (1.32%)
Apr 30, 2026, 3:04 PM CST
SHE:301111 Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Cash & Equivalents | 124.35 | 143.14 | 159.1 | 131.11 | 179.21 | 485.35 |
Short-Term Investments | - | - | 128.25 | 141.14 | 190.97 | 20.42 |
Trading Asset Securities | 77.56 | 77.59 | 34.81 | 72.86 | 81.32 | 48.04 |
Cash & Short-Term Investments | 201.9 | 220.73 | 322.16 | 345.11 | 451.51 | 553.81 |
Cash Growth | -34.46% | -31.49% | -6.65% | -23.57% | -18.47% | 312.00% |
Accounts Receivable | 109.16 | 97.42 | 85.23 | 74 | 71.01 | 97.57 |
Other Receivables | 3.8 | 2.92 | 2.69 | 3.34 | 2.01 | 1.94 |
Receivables | 112.95 | 100.35 | 87.91 | 77.34 | 73.02 | 99.51 |
Inventory | 75.76 | 77.31 | 90.13 | 83.43 | 70.69 | 51.91 |
Prepaid Expenses | - | - | 0 | - | - | - |
Other Current Assets | 305.91 | 302.52 | 14.99 | 3.78 | 5.73 | 3.62 |
Total Current Assets | 696.52 | 700.9 | 515.2 | 509.66 | 600.95 | 708.84 |
Property, Plant & Equipment | 81.64 | 83.51 | 115.24 | 58.59 | 55.94 | 74.55 |
Long-Term Investments | 51.62 | 42.5 | 219.41 | 238.08 | 181.28 | 33.47 |
Goodwill | 7.32 | 7.32 | 7.32 | - | - | - |
Other Intangible Assets | 29.01 | 29.52 | 29.88 | 30.18 | 7.83 | 7.89 |
Long-Term Deferred Tax Assets | 14.54 | 13.81 | 13.91 | 8.51 | 8.52 | 1.22 |
Long-Term Deferred Charges | 15.36 | 15.79 | 28.71 | 0.4 | - | - |
Other Long-Term Assets | 1.89 | 0.76 | 3.49 | 10.13 | 2.56 | 0.23 |
Total Assets | 897.92 | 894.13 | 933.17 | 855.54 | 857.07 | 826.2 |
Accounts Payable | 67.32 | 63.72 | 56 | 34.87 | 29.04 | 37.59 |
Accrued Expenses | 4.63 | 7.49 | 12.71 | 11.4 | 17.25 | 9.38 |
Current Portion of Long-Term Debt | 5.72 | 5.24 | - | - | - | - |
Current Portion of Leases | - | - | 1.29 | 3.87 | 0.16 | 0.93 |
Current Income Taxes Payable | 5.15 | 5.09 | 1.29 | 0.2 | 9.85 | 5.09 |
Current Unearned Revenue | 17.27 | 13.49 | 12.44 | 5.39 | 26.88 | 5.66 |
Other Current Liabilities | 7.47 | 7.24 | 11.13 | 10.24 | 10.19 | 7.44 |
Total Current Liabilities | 107.56 | 102.28 | 94.85 | 65.97 | 93.36 | 66.08 |
Long-Term Leases | 39.41 | 40.24 | 70.86 | 10.09 | - | 0.16 |
Long-Term Unearned Revenue | 0.33 | 0.39 | 0.7 | 1.28 | 5.04 | 7.45 |
Long-Term Deferred Tax Liabilities | - | - | - | - | - | 1.66 |
Total Liabilities | 147.3 | 142.91 | 166.42 | 77.33 | 98.39 | 75.34 |
Common Stock | 160 | 160 | 160 | 160 | 160 | 160 |
Additional Paid-In Capital | 405.78 | 405.78 | 406.94 | 406.94 | 406.94 | 406.94 |
Retained Earnings | 181.6 | 184.91 | 197.4 | 209.23 | 191.73 | 183.91 |
Total Common Equity | 747.39 | 750.69 | 764.34 | 776.17 | 758.67 | 750.85 |
Minority Interest | 3.23 | 0.53 | 2.41 | 2.03 | -0 | - |
Shareholders' Equity | 750.62 | 751.22 | 766.75 | 778.21 | 758.67 | 750.85 |
Total Liabilities & Equity | 897.92 | 894.13 | 933.17 | 855.54 | 857.07 | 826.2 |
Total Debt | 45.13 | 45.49 | 72.15 | 13.95 | 0.16 | 1.09 |
Net Cash (Debt) | 156.77 | 175.24 | 250.01 | 331.15 | 451.35 | 552.72 |
Net Cash Growth | -35.91% | -29.91% | -24.50% | -26.63% | -18.34% | 311.19% |
Net Cash Per Share | 1.05 | 1.17 | 1.80 | 2.08 | 2.84 | 4.64 |
Filing Date Shares Outstanding | 159.74 | 118.41 | 160 | 160 | 160 | 160 |
Total Common Shares Outstanding | 159.74 | 118.41 | 160 | 160 | 160 | 160 |
Working Capital | 588.96 | 598.63 | 420.34 | 443.69 | 507.59 | 642.77 |
Book Value Per Share | 4.68 | 6.34 | 4.78 | 4.85 | 4.74 | 4.69 |
Tangible Book Value | 711.05 | 713.85 | 727.13 | 745.99 | 750.85 | 742.96 |
Tangible Book Value Per Share | 4.45 | 6.03 | 4.54 | 4.66 | 4.69 | 4.64 |
Buildings | - | - | 76.38 | 68.76 | 74.73 | 79.72 |
Machinery | - | - | 86.7 | 78.07 | 78.59 | 93.14 |
Construction In Progress | - | - | - | 0.72 | 0.72 | - |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.